Fungal Infections

Diagnosis and Treatment

• The American College of Physicians recommends topical antifungal agents such as clotrimazole 1% cream, miconazole 2% cream, or nystatin powder/cream applied 2-3 times daily for 7-14 days as the first-line treatment for candidal diaper rash, as supported by the Infectious Diseases Society of America 1, 2
• Clotrimazole 1% cream or miconazole 2% cream applied twice daily for 7-14 days are recommended as first-line prescription treatments for most common fungal skin infections 1
• Alternative topical azole antifungals include miconazole cream 2% and ketoconazole cream 2%, applied 2-3 times daily for 14 days, with a strength of evidence rated as moderate by the Infectious Diseases Society of America 1, 3
• For severe or persistent cases of candidal diaper rash, consider oral fluconazole, especially if there is extensive involvement, and evaluate for underlying conditions such as immunodeficiency or diabetes, and rule out resistant Candida species, as recommended by the Infectious Diseases Society of America with a strength of evidence rated as high 1
• The Infectious Diseases Society of America recommends fluconazole at a dosage of 200-400 mg (3-6 mg/kg) daily for 2 weeks for fluconazole-susceptible organisms, with treatment duration extended based on clinical response and organism susceptibility, and a strength of evidence rated as high 1
• For severe infections, consider starting with a loading dose of 800 mg (12 mg/kg), then 400 mg (6 mg/kg) daily, as recommended by the American Academy of Dermatology with a strength of evidence rated as moderate 4

Infection-Specific Treatment

Management of Resistant Species

• For C. glabrata, the preferred first-line treatment is an echinocandin (caspofungin, micafungin, anidulafungin), as recommended by the Infectious Diseases Society of America with a strength of evidence rated as high 4
• For C. glabrata, an alternative treatment is Amphotericin B deoxycholate 0.3-0.6 mg/kg daily for 1-7 days with or without oral flucytosine, as recommended by the Infectious Diseases Society of America with a strength of evidence rated as moderate 1
• For C. krusei, use Amphotericin B deoxycholate 0.3-0.6 mg/kg daily for 1-7 days, as recommended by the Infectious Diseases Society of America with a strength of evidence rated as moderate 1
• For fluconazole-resistant species, consider amphotericin B deoxycholate bladder irrigation (50 mg/L sterile water daily for 5 days), as recommended by the Infectious Diseases Society of America with a strength of evidence rated as moderate 1
• For fluconazole-refractory disease, consider itraconazole solution 200 mg once daily or posaconazole suspension, as recommended by the Infectious Diseases Society of America with a strength of evidence rated as low 1

Prevention and Supportive Care

• Keeping the area clean and dry with gentle cleansing using mild soap-free cleansers and thorough drying after bathing is recommended, consider using absorptive powders like cornstarch (avoid talc), as suggested by the American Academy of Dermatology with a strength of evidence rated as low 6
• Applying zinc oxide-based barrier creams after treatment and considering petroleum jelly to protect fissures and surrounding skin can help in barrier protection, as suggested by the American Academy of Dermatology with a strength of evidence rated as low 6
• Reducing friction and moisture by wearing light, non-constricting, absorbent cotton clothing and avoiding synthetic fabrics and tight clothing is advised, as suggested by the American Academy of Dermatology with a strength of evidence rated as low 6
• Remove indwelling bladder catheters if present, as recommended by the Infectious Diseases Society of America with a strength of evidence rated as moderate 1

Monitoring and Follow-up

• Ophthalmological evaluation is recommended in cases of candidemia, preferably within the first week, as suggested by the Infectious Diseases Society of America with a strength of evidence rated as moderate 1
• Daily blood cultures until negativity for at least two consecutive samples are recommended by the European Society of Clinical Microbiology and Infectious Diseases with a strength of evidence rated as high 7
• Monitoring of renal and hepatic function, as well as vigilance for possible drug interactions, especially with azoles, is recommended by the Infectious Diseases Society of America with a strength of evidence rated as moderate 1, 2
• Patients should be educated on the importance of completing the full treatment course and adhering to the prescribed regimen, as highlighted by the Clinical Infectious Diseases guidelines with a strength of evidence rated as high 1
• Always attempt to identify the causative organism before starting treatment, as susceptibility patterns vary significantly, as recommended by the Infectious Diseases Society of America with a strength of evidence rated as high 4
• Continue treatment until complete resolution of symptoms and negative cultures, as recommended by the Infectious Diseases Society of America with a strength of evidence rated as high 4
• Address underlying conditions (diabetes, immunosuppression) and remove predisposing factors (catheters, foreign bodies), as recommended by the Infectious Diseases Society of America with a strength of evidence rated as moderate 1